Last updated on July 2020

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options


Brief description of study

This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.

Clinical Study Identifier: NCT02650401

Find a site near you

Start Over

Primary Children's Hospital

Salt Lake City, UT United States
  Connect »

Oregon Health & Science Uni

Portland, OR United States
  Connect »

Rady Childrens Hospital

San Diego, CA United States
  Connect »

Cook Childrens Medical Center

Fort Worth, TX United States
  Connect »

Johns Hopkins University

Baltimore, MD United States
  Connect »

Royal Victoria Infirmary; Pharmacy

Newcastle upon Tyne, United Kingdom
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.